Why is Sionna Therapeutics stock sliding today?

Sionna Therapeutics shares plummeted 3.0% in post-market trading following a significant strategic overhaul, which included laying off 46% of its workforce and shifting focus to a new Phase 2a trial, AscenSION CF, slated for 2027. The company simultaneously abandoned SION-719 as an add-on treatment, following the failure of the PreciSION CF trial to meet its primary goal.

Raymond James downgraded Sionna's stock to Market Perform from Strong Buy, further exacerbating investor concerns. The workforce cuts are expected to incur $6.4 million in restructuring costs, though they are projected to extend the company's cash reserves until the second half of 2029. However, the market's reaction was driven by the narrowed pipeline rather than the improved financial outlook.

Competitors like Vertex Pharmaceuticals remain strong despite setbacks in Sionna's pipeline. The stock's decline was not influenced by broader market conditions, which saw only slight gains in U.S. indices.